Educational guide
Halotestin and LGD-4033 Interaction: Avoid | Peptide Database
Compound Profiles Halotestin Oral Anabolic Steroid | Extreme Strength & Aggression Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural mod
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Compound Profiles
Halotestin
Oral Anabolic Steroid | Extreme Strength & Aggression
Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue.
LGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Halotestin with LGD-4033?
Combining Halotestin with LGD-4033 is not recommended. Both Halotestin and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is Halotestin and LGD-4033 safe together?
This combination carries significant risk. Both Halotestin and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between Halotestin and LGD-4033?
Both Halotestin and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.
How should I time Halotestin and LGD-4033?
Halotestin has a half-life of ~9.5 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.